Adagrasib Shows Durable Clinical Benefit in Advanced KRAS-Mutant NSCLC

Adagrasib has shown durable clinical activity in patients with advanced KRASG12C-mutant NSCLC, according to updated results from the KRYSTAL-1 trial.

Related Keywords

Detroit ,Michigan ,United States ,Shirish Gadgeel ,Henry Ford Cancer Institute In Detroit ,Mirati Therapeutics Inc ,Henry Ford Cancer Institute ,Mirati Therapeutics ,